MarketPulse

Phase II trial

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Mink Therapeutics

MiNK Therapeutics Shows Promise in Gastric Cancer With 77% Disease Control Rate

MiNK Therapeutics reported Phase II data for agenT-797 combination therapy in PD-1 refractory gastroesophageal cancer, achieving 77% disease control with improved survival metrics.
INKTPhase II trialiNKT cell therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Immutep Limited

Immutep Wins FDA Orphan Drug Nod for Sarcoma Treatment Eftilagimod Alfa

Immutep gains FDA orphan drug designation for eftilagimod alfa in soft tissue sarcoma, with Phase II trial results exceeding efficacy targets by 47%.
MRKIMMPFDA approvalorphan drug designation
GlobeNewswire Inc.GlobeNewswire Inc.··Mink Therapeutics

MiNK Therapeutics Advances iNKT Cell Therapy for Hard-to-Treat Gastric Cancer

MiNK Therapeutics will present Phase II data on agenT-797 combined immunotherapy for PD-1 refractory gastroesophageal cancer at AACR 2026.
INKTimmunotherapyPhase II trial
GlobeNewswire Inc.GlobeNewswire Inc.··Roche

Roche's Weight-Loss Drug Shows Promise With Double-Digit Results in Phase II Trial

Roche's petrelintide demonstrates 10.7% weight reduction in Phase II, positioning the amylin analog as a potential alternative to dominant GLP-1 drugs with favorable tolerability. Phase III trials planned.
RHHBYZLDPYclinical resultsweight loss